Background: Guidelines recommend sodium–glucose cotransporter-2 (SGLT2) inhibitors
and glucagon-like peptide-1 (GLP1) receptor agonists as second-line therapy for patients …

Aims To identify all cardiovascular disease risk prediction models developed in patients with
type 2 diabetes or in the general population with diabetes as a covariate updating previous …

Background Diabetes mellitus is a chronic and complex disease, increasing in prevalence
and consequent health expenditure. Cost-effectiveness models with long time horizons are …

The lack of effective, scalable solutions for lifestyle treatment is a global clinical problem,
causing severe morbidity and mortality. We developed a method for lifestyle treatment that …

Objectives To estimate 13 equations that predict clinically plausible risk factor time paths to
inform the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model version 2 …

Background: Intensive glycemic control in type 2 diabetes (glycated hemoglobin HbA1c
level< 7%) is an established, cost-effective standard of care. However, guidelines …

Objective This study aimed to evaluate the long-term cost-effectiveness of once-weekly
subcutaneous semaglutide versus polyethylene glycol loxenatide (PEG-loxenatide) in …

Background We performed a systematic overview of the cost-effectiveness analyses (CEAs)
comparing Non-insulin antidiabetic drugs (NIADs) with other NIADs for the treatment of type …

Background For end-users of diabetes models that include UKPDS 82 risk equations, an
important question is how well these new equations perform. Consequently, the principal …

Abstract Background The Economic and Health Outcomes Model of Type 2 Diabetes
Mellitus (ECHO-T2DM) was developed to address study questions pertaining to the cost …